证券代码：002693 证券简称：双成药业 公告编号：2023-060 海南双成药业股份有限公司 关于部分理财产品逾期兑付的风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2022年9月28日，公司使用闲置自有资金2,000万元购买隆晟1号的理财产品， 该理财产品年化预期收益率为7.0%，产品期限自2022年9月29日至2023年9月28 日。公司于2022年12月28日收到上述信托计划部分投资收益34.52万元，截至本 公告披露日，上述信托计划本金及剩余投资收益尚未收回。公司已就该信托计划 逾期兑付的事宜与受托人进行了沟通，截至本公告披露日，公司未收到受托人的 正式文件回复，后续公司将密切关注该信托产品的相关进展情况，继续督促受托 人尽快兑付投资本金及剩余收益，并及时履行信息披露义务。 除上述的理财产品以外，2023年4月17日，公司使用闲置自有资金3,000万元 购买隆晟1号的理财产品，产品期限自2023年4月18日至2023年10月17日。截至本 公告披露日该理财产品尚未到期。 三、公司拟采取的相关措施 公司正在积极联系各相关方，督促受托人 ...

证券代码：002693 证券简称：双成药业 公告编号：2023-059 海南双成药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据深交所《股票上市规则》规定应予 1、前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已对公司股票交易价格产生较大影 响的未公开重大信息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、经核实，公司及控股股东、实际控制人不存在关于公司的应披露而未披 露的重大事项，也不存在处于筹划阶段的重大事项。 5、经核实，公司控股股东、实际控制人在公司股票交易异常波动期间未买 卖公司股票。 6、经自查，公司不存在违反信息公平披露的情形。 海南双成药业股份有限公司（以下简称"公司"）（证券简称：双成药业， 证券代码：002693）股票交易价格于 2023 年 9 月 15 日、2023 年 9 月 18 日连续 两个交易日收盘价格涨幅偏离值累计超过 20%。根据深圳证 ...

海南双成药业股份有限公司 关于获得政府补助的公告 证券代码：002693 证券简称：双成药业 公告编号：2023-058 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"、"双成药业"）累计收到与 收益相关的政府补助金额合计人民币 237.78 万元（不含公司前期已披露政府补 助），占公司经审计的最近一个会计年度归属于上市公司股东的净利润 10%以上 且绝对金额超过 100 万元，具体情况如下： 注：上表所述政府补助均与公司日常经营相关，不具有可持续性。 二、补助的类型及其对公司的影响 1、补助的类型 公司将按照《企业会计准则第 16 号—政府补助》的规定，与资产相关的政 府补助，是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与 收益相关的政府补助，是指除与资产相关的政府补助之外的政府补助。与收益相 关的政府补助用于补偿企业以后期间的相关费用或损失的，确认为递延收益，并 在确认相关费用的期间，计入当期损益；用于补偿企业已发生的相关费用或损失 获得补助 的日期 获得补助 主体 获得补助的主体原因及项目 补助 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥139,013,360.10, representing a 9.62% increase compared to ¥126,814,078.76 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached ¥8,790,256.43, a significant increase of 584.62% from a loss of ¥1,813,831.34 in the previous year[22]. - The basic earnings per share improved to ¥0.0214, compared to a loss of ¥0.0045 per share in the same period last year, marking a 575.56% increase[22]. - The net cash flow from operating activities was negative at -¥19,703,531.96, worsening by 232.05% from -¥5,933,898.11 in the previous year[22]. - Total assets at the end of the reporting period were ¥903,149,462.01, a decrease of 0.86% from ¥911,018,789.08 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 3.85% to ¥533,305,230.27 from ¥513,547,960.18 at the end of the previous year[22]. - The company reported non-recurring gains of ¥10,305,471.24, primarily from government subsidies and asset disposals[26]. - The weighted average return on net assets was 1.69%, an increase of 2.07% compared to -0.38% in the previous year[22]. - The company achieved a revenue of CNY 139.01 million, representing a year-on-year growth of 9.62%, and a net profit attributable to shareholders of CNY 8.79 million, up 584.62%[37]. Industry Context - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,249.6 billion in the first half of 2023, a year-on-year decline of 2.9%, with total profits dropping by 17.1% to CNY 179.45 billion[30]. - The company has multiple peptide products approved and sold in developed countries, including the injection of thymosin alpha1 (brand name "Jitai"), which has passed the consistency evaluation of quality and efficacy for generic drugs in China[31]. - The injection of bivalirudin has received marketing approval from both the US FDA and the National Medical Products Administration in China, primarily used for unstable angina patients undergoing percutaneous coronary intervention[33]. - The company has developed nearly 10 peptide products in recent years, focusing on high market potential and complex synthesis challenges[36]. Operational Strategy - The company’s main sales strategy involves a recruitment model, with business managers and market personnel stationed in various regions to enhance product distribution[36]. - The company has advanced production facilities that have passed inspections by the US FDA and EU GMP, ensuring compliance with international quality standards[36]. - The company has a comprehensive technical system for the synthesis, purification, analysis, and quality assurance of chemical synthetic peptide drugs[32]. - The company is recognized as a national high-tech enterprise with a complete R&D technology team in the peptide drug field[31]. Financial Management - The cost of sales decreased by 4.49% to ¥39,835,643.04 from ¥41,706,732.55, contributing to an improved gross margin[42]. - Research and development expenses increased by 5.88% to ¥14,971,757.93, indicating continued investment in innovation[43]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥36,560,791.72, a 374.01% improvement from -¥13,343,110.07 in the previous year[43]. - The industrial segment accounted for 93.34% of total revenue, with a 13.03% increase in revenue to ¥129,757,777.58[44]. - The peptide products segment saw a revenue increase of 27.43% to ¥66,327,721.63, representing 47.71% of total revenue[44]. Risk Management - The company faces various risks including policy changes, price fluctuations of raw materials, and potential talent loss, which are detailed in the risk management section[5]. - The company faces risks from industry policy changes, rising raw material prices, and concentrated product lines, and plans to adjust strategies accordingly[63][64]. - The company anticipates increased financial risk due to expanding export operations and potential foreign exchange fluctuations, implementing measures to mitigate these risks[67]. - The company faces price risks due to multiple national policy-driven price reductions in pharmaceuticals, which may continue to affect sales prices[66]. Environmental Compliance - The company has established a comprehensive pollution management system and treatment facilities to ensure compliance with environmental regulations, reducing environmental risk[66]. - The company has successfully renewed its pollution discharge permit, valid from February 24, 2023, to February 23, 2028[85]. - In 2023, the company invested CNY 1.46 million in environmental protection facilities and daily expenses, focusing on construction, operation, maintenance, and testing of environmental protection equipment[87]. - The company has reduced nitrogen oxide emissions by approximately 50% per boiler after low-nitrogen modifications to two existing boilers, achieving a concentration below 50 mg/Nm³[88]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[72]. - The company has approved a stock option and restricted stock incentive plan, granting 7 million restricted shares at 1.91 CNY per share and 7 million stock options at 3.82 CNY per option[74]. - The total number of shares increased from 414,737,000 to 416,184,180, with an increase of 1,447,180 shares due to stock options and restricted stock incentives[135]. - The total number of common shareholders at the end of the reporting period was 42,659[137]. Governance and Compliance - The company completed the election of the fifth board of directors and the supervisory board, ensuring stable governance and management[118]. - The semi-annual financial report was not audited[96]. - The company did not experience any major litigation or arbitration matters during the reporting period[98]. - The company has not reported any changes in accounting policies or prior period errors during this reporting period[171].

投资者关系活动记录表 编号：2023-02 证券代码： 002693 证券简称：双成药业 海南双成药业股份有限公司 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | 媒体采访 业绩说明会 □ √ | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 投资者网上提问 | | 时间 | 年 月 日 (周五) 下午 2023 5 26 14:30~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事会秘书于晓风 | | 员姓名 | 2、财务总监王旭光 | | | 3、证券事务代表李芬 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、公司应该心系投资者，而不是要割韭菜了才想起投资者 | | | 尊敬的投资者感谢您的关注！ | | | 2、请介绍一下贵司 CM ...

证券代码：002693 证券简称：双成药业 公告编号：2023-043 海南双成药业股份有限公司 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南证监局将与深圳市全景网络有限公司、海南上市公司协会联合举办 "海南辖区投资者网上集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为：http://rs.p5w.net。 届时，海南双成药业股份有限公司主要高管人员将参加本次活动，通过网络 在线交流形式，就公司 2022 年年报披露、财务数据、公司治理、内部控制、发 展战略、经营状况、现金分红、重大事项、可持续发展等投资者所关心的问题， 与投资者进行"一对多"形式的沟通与交流。欢迎广大投资者踊跃参与。 特此公告。 2023 年 5 月 17 日 关于参加"2022 年度海南辖区上市公司业绩说明会"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司董事会 ...

证券代码：002693 证券简称：双成药业 海南双成药业股份有限公司 投资者关系活动记录表 编号：2023-01 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2022年度网上业绩说明会的全体投资者 | | 时间 | 2023年05月15日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） | | 上市公司接待人员姓名 | 董事、总经理 Jianming Li | | | 独立董事 肖建华 | | | 副总经理、董事会秘书 于晓风 | | | 财务总监 王旭光 | | | 1 .23年第一季度公司表现亮眼，第二季度经营情况如何？ | | | 答:尊敬的投资者，您好。第二季度经营正常，具体情况请关注 | | 投资者关系活动主要内容 | 公司半年报。营业收入与市场变化有关，具有波动性，请注意投资 | | 介绍 | 风险。 | | ...

Financial Performance - The company's revenue for Q1 2023 was ¥81,485,154.92, representing an increase of 11.27% compared to ¥73,230,987.79 in the same period last year[2] - Net profit attributable to shareholders reached ¥4,505,619.82, a significant increase of 517.11% from ¥730,119.24 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥1,599,812.27, up 125.66% from a loss of ¥6,233,934.62 in the previous year[2] - Basic earnings per share increased to ¥0.0110, reflecting a growth of 511.11% compared to ¥0.0018 in the same period last year[2] - Total operating revenue for Q1 2023 was CNY 81,485,154.92, an increase of 11.5% compared to CNY 73,230,987.79 in the same period last year[31] - Net profit for Q1 2023 was CNY 103,484.98, a significant recovery from a net loss of CNY 2,492,564.24 in the previous year[32] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0110, compared to CNY 0.0018 in the same period last year, representing a growth of 511.1%[32] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥19,881,051.09, a decline of 30.07% compared to -¥15,284,942.57 in the same period last year[2] - The company reported a decrease in cash and cash equivalents from RMB 12,196,777.95 at the beginning of the year to RMB 5,920,315.43 at the end of the quarter[26] - The company's total current assets decreased from RMB 252,394,374.44 at the beginning of the year to RMB 241,151,591.67 at the end of the quarter[28] - The total cash and cash equivalents at the end of the period were 5,920,315.43 CNY, down from 14,375,610.63 CNY in the previous period, indicating a decrease in liquidity[34] - The total cash outflow from operating activities was 100,818,167.95 CNY, compared to 95,615,637.78 CNY in the previous period, indicating higher operational costs[33] Investment and Financing Activities - The company reported a 129.10% increase in cash received from investment recoveries, indicating improved cash flow management[9] - Total cash inflow from investment activities was 150,408,649.83 CNY, significantly higher than 63,667,129.39 CNY in the previous period, reflecting increased investment recovery[34] - The net cash flow from investment activities improved to 20,985,778.54 CNY, compared to -41,225,949.49 CNY in the previous period, showing a positive turnaround[34] - Cash inflow from financing activities decreased to 4,392,700.00 CNY from 51,708,400.00 CNY in the previous period, indicating reduced borrowing[34] - The net cash flow from financing activities was -1,979,509.71 CNY, a significant drop from 49,291,851.39 CNY in the previous period, highlighting challenges in financing[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥890,784,444.32, a decrease of 2.22% from ¥911,018,789.08 at the end of the previous year[2] - The company's total liabilities decreased to CNY 309,027,615.64 from CNY 330,076,360.29 at the beginning of the year, a reduction of approximately 6.4%[30] - The total equity attributable to shareholders of the parent company increased to CNY 518,764,494.90 from CNY 513,547,960.18, marking a growth of 1.4%[30] - The company's total non-current assets decreased from RMB 658,624,414.64 at the beginning of the year to RMB 649,632,852.65 at the end of the quarter[28] Research and Development - Research and development expenses grew by 46.39% year-on-year, indicating increased investment in R&D projects[7] - Research and development expenses rose to CNY 2,589,268.35, up 46.5% from CNY 1,768,762.68 in the previous year[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,474[11] - Hainan Shuangcheng Investment Co., Ltd. holds 32.92% of shares, with 136,516,546 shares pledged[11] - HSP Investment Holdings Limited owns 15.58% of shares, totaling 64,599,379 shares, with 16,210,000 shares pledged[11] - The top ten shareholders include both domestic and foreign entities, with significant shareholding by Hainan Shuangcheng Investment Co., Ltd. and HSP Investment Holdings Limited[11] - The company has implemented a stock option and restricted stock incentive plan, granting 7 million restricted shares at RMB 1.91 per share and 7 million stock options at RMB 3.82 per option[13] Strategic Agreements - The company signed a product rights transfer agreement with Chongqing Laimei Pharmaceutical Co., Ltd. and Hangzhou Boying Health Technology Co., Ltd. for a total contract amount of RMB 32 million, acquiring all tangible and intangible assets related to the acetate triptorelin injection in China[20] - The company entered into a licensing and supply agreement with Meitheal Pharmaceuticals, Inc. and Hong Kong King-Friend Industrial Co., Ltd. for the exclusive rights to develop and produce paclitaxel injection (albumin-bound) in the U.S., with a total milestone payment of USD 6 million, of which USD 3 million has been received[23] Employee Compensation and Incentives - The company reported a decrease in employee compensation payable from CNY 8,596,015.63 to CNY 5,860,557.02, a decline of 31.5%[30] - The company’s incentive plan aligns with its strategic goals to enhance employee motivation and retention[19] Audit and Reliability - The first quarter report was not audited, which may affect the reliability of the financial data presented[35] - The company did not report any new product launches or technological advancements during this quarter[36]

证券代码：002693 证券简称：双成药业 公告编号：2023-035 海南双成药业股份有限公司 会议召开时间：2023 年 5 月 15 日（星期一）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日在 巨潮资讯网上披露了《2022 年年度报告》及其摘要。为便于广大投资者更加全 面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 5 月 15 日（星 期一）15:00-17:00 在"价值在线"（www.ir-online.cn）举办海南双成药业股 份有限公司 2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投 资者的意见和建议。 一、说明会召开的时间、地点和方式 四、联系人及咨询办法 联系人：双成药业证券部 电话：0898-68592978 邮箱：lifen@shuangchengmed.com ...

Financial Performance - The company's operating revenue for 2022 was ¥274,754,114.70, a decrease of 14.22% compared to ¥320,293,514.52 in 2021[21] - The net profit attributable to shareholders in 2022 was ¥9,012,396.69, representing a significant increase of 144.34% from a loss of ¥20,325,073.94 in 2021[21] - The net cash flow from operating activities was ¥25,217,762.02, an increase of 7.07% compared to ¥23,553,573.54 in the previous year[21] - The total assets at the end of 2022 amounted to ¥911,018,789.08, reflecting a growth of 6.61% from ¥854,556,164.94 at the end of 2021[21] - The net assets attributable to shareholders increased by 6.58% to ¥513,547,960.18 at the end of 2022, up from ¥481,848,410.05 in 2021[21] - The basic earnings per share for 2022 was ¥0.02, a turnaround from a loss of ¥0.05 per share in 2021, marking a 140.00% improvement[21] - The weighted average return on net assets was 1.80% in 2022, an increase of 6.01 percentage points from -4.21% in 2021[21] - The company reported a net profit excluding non-recurring gains and losses of -¥36,881,064.99 in 2022, a slight improvement of 6.35% from -¥39,383,459.22 in 2021[21] Revenue and Profit Trends - The company's total revenue for Q1 2022 was ¥73,230,987.79, which decreased to ¥53,583,090.97 in Q2, then increased to ¥71,049,140.92 in Q3, and reached ¥76,890,895.02 in Q4[23] - The net profit attributable to shareholders was ¥730,119.24 in Q1, but turned negative in Q2 and Q3 with losses of ¥2,543,950.58 and ¥1,806,463.72 respectively, before recovering to ¥12,632,691.75 in Q4[23] - Non-operating income for 2022 totaled ¥45,893,461.68, significantly higher than ¥19,058,385.28 in 2021, driven by gains from asset disposals and government subsidies[23] Industry Context - The pharmaceutical industry in China saw a revenue decline of 1.6% in 2022, with total revenue of ¥2,911.14 billion and a profit drop of 31.8% to ¥428.87 billion[28] - The government health expenditure in 2021 was ¥2,075.18 billion, accounting for 27.4% of total health spending, indicating a strong reliance on public funding in the healthcare sector[28] R&D and Innovation - The company is focusing on innovation and collaboration with small and medium enterprises to enhance competitiveness and resilience in the supply chain[29] - The company has developed multiple peptide drugs and 20 other therapeutic drugs, with significant international approvals including from the FDA and EMA[39] - The company focuses on the research and development of peptide products, with nearly 10 new peptide products in various stages of approval and development[42] - The company received FDA approval for the injection of Eptifibatide (75mg/100mL) and registration for Acetate Triptorelin injection (1ml:0.1mg)[49] Market Strategy - The company plans to enhance its R&D capabilities, focusing on the development of peptide raw materials and formulations, while increasing R&D investment and stabilizing the R&D team[85] - The company aims to expand its market presence through international collaborations, including patent licensing and joint development, to introduce advanced drug technologies into the domestic market[85] - The company plans to accelerate the submission of DMF and ANDA applications in the US and EU to enhance internationalization[47] Financial Management - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company reported a significant decline in investment income, down 52.81% to ¥4,689,841.85, primarily due to reduced financial investment returns[69] - The total net increase in cash and cash equivalents was -¥14,820,845.53, a decline of 193.68% compared to the previous year[66] Risk Factors - The company faces various risks including industry policy changes, drug price reductions, and financial risks, which are detailed in the report[5] - The company is exposed to financial risks from foreign exchange fluctuations and increasing accounts receivable and inventory, which may pressure operational funds[95] - The company is addressing the risk of drug price declines due to national policies by enhancing product quality and seizing market opportunities[94] Corporate Governance - The company emphasized its commitment to improving corporate governance and compliance with regulatory requirements, having held 3 shareholder meetings during the reporting period[101] - The board of directors held 13 meetings, ensuring diligent oversight and independent opinions on significant matters[103] - The company has established a fair and transparent performance evaluation system for directors and senior management, enhancing team cohesion and operational efficiency[104] Environmental Responsibility - The company has established a comprehensive pollution management system to comply with environmental regulations and reduce environmental risks associated with production[93] - The company invested over 4.84 million RMB in environmental protection facilities and daily expenses, focusing on construction, operation, maintenance, and testing of environmental protection equipment[168] - The company has not faced any administrative penalties due to environmental issues during the reporting period[168] Shareholder Relations - The company confirmed that it operates independently from its controlling shareholder, maintaining autonomy in business operations and decision-making[102] - The company has a clear asset ownership structure, with complete control over its production and operational facilities, ensuring no asset misappropriation by controlling shareholders[109] - The company has committed to a cash dividend distribution policy, aiming for a cumulative cash distribution of at least 30% of the average distributable profit over the past three years from 2021 to 2023[178]